New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Sanofi buys a drug from Dren Bio to claim a stake in the emerging field of deep B-cell depletion for autoimmune diseases. Skip to main content Friday 20 June 2025 . BlueSky linkedin youtube rss ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters ...

Bioinspired materials articles from across Nature Portfolio. Atom; RSS Feed; Definition. Bioinspired materials are synthetic materials whose structure, properties or function mimic those of ...